Show simple item record

dc.rights.licenceAttribution-NonCommercial 4.0 International*
dc.contributor.authorAschner Montoya, Pablo
dc.date.accessioned2021-03-01T20:26:15Z
dc.date.available2021-03-01T20:26:15Z
dc.date.created2013
dc.identifierhttps://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.htmlspa
dc.identifier.issn1758-1907spa
dc.identifier.urihttp://hdl.handle.net/10554/53144
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.titleCanagliflozin for the treatment of adults with Type 2 diabetesspa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.description.comunidadAdultosspa
dc.description.abstractenglishCanagliflozin is a competitive, reversible and potent inhibitor of SGLT2 that lowers the renal threshold for glucose and consequently increases urinary glucose excretion in people with Type 2 diabetes with a blood glucose level above 70–90 mg/dl. Its oral administration in daily doses of 100 and 300 mg in onotherapy, dual therapy or triple therapy including insulin produces a mean HbA1c reduction of 0.7 and 0.85%, respectively, when compared with placebo, a similar reduction to sitagliptin and glimepiride. There is also a modest reduction in weight with both doses. The main adverse effects are genital fungal infections, particularly in women, and, less frequently, urinary tract infections.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.type.localArtículosspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.description.orcidhttps://orcid.org/0000-0002-6860-3620spa
dc.relation.citationstartpage343spa
dc.relation.citationendpage350spa
dc.relation.ispartofjournalDiabetes Managementspa
dc.description.indexingN/Aspa
dc.relation.citationvolume3spa
dc.relation.citationissue4spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International